Introduction
In the last decades, DES have turned out efficient in treatment of coronary heart disease (CHD). On the basis of its quality in specific drug application, DES achieved great success in the decrease of in-stent restenosis incidents. Nevertheless, for a better understanding of their drug release behaviour and for a reduction of later experimental in vivo studies, further research is required. In vitro perfusion systems represent possible opportunities to overcome the limitations connected with standard release methods. One example for such a system is the vessel-simulating flow-through cell developed by Seidlitz et al. [1] . This vessel-simulating flow-through cell allows examining the release and distribution of pharmaceuticals from DES independent of animal models under standardised dissolution testing by the use of hydrogel-based matrices serving as an alternative to tissue. As a complementary model, the in vitro perfusion culture system presented here uses porcine arteries. Over a time period of 72 h these arteries are still functional and samples can be taken. For the investigations carried out metallic coronary stents coated with the biodegradable polymer poly(L-lactide) (PLLA) and the hydrophobic fluorescent dye fluorescein diacetate (FDAc) were implanted into the artery segments. Because the release properties of FDAc are similar to the well-established, antiproliferative drug paclitaxel (PTX), FDAc serves as a model substance [2] . Due to its fluorescent properties FDAc enables us to investigate the drug release behaviour by qualifying its distribution within the vessel wall. Simultaneous quantification within the release medium is achieved by liquid chromatography-mass spectrometry (LC-MS).
Materials and Methods
Porcine arteries were freshly prepared, clamped and cultured into an in vitro perfusion culture system (tube chamber system TCS 2c , Provitro GmbH, Berlin, Germany) (Fig. 1) . Metallic coronary stents (diameter 3.5 mm, length 13 mm) were spray-coated with a mixture of PLLA and FDAc (82.5/17.5% w/w, absolute coating mass 457-486 µg) as described elsewhere [3] . The coated stents were implanted into the artery segments and flowed through with NaCl/Tween20 solution (0.9%w/0.06%w) under a constant flow of 4 mL/min according to [4] . This artificial medium was required for the realization of FDAc solubility and measurement by LC-MS where phosphate-containing media are unsuitable. Then samples of the perfusion medium were taken at defined time points over a period of 72 h. The extraction of the released FDAc from artery tissue was performed after stent explantation as follows: The stented artery tissue was frozen in liquid nitrogen, cut in small pieces and pulverized. The resulting powder was extracted by adding 0.5 mL methanol. The suspension was vortexed for 30 min followed by repeated centrifugation and removal of the supernatant. 
Results
The qualitative analysis by CLSM showed increased fluorescence of artery segments with stents applied, exemplarily shown in Fig. 2a , compared to segments without stents applied that were taken as reference (Fig. 2c) . As additional confirmation of the FDAc release a total amount of approx. 0.1 mg FDAc/g tissue quantified by LC-MS was found after 72 h. Furthermore, a sustained FDAc release measured as FDAc concentrations in the perfusion medium at different time points could be demonstrated. After 72 h the absolute cumulative FDAc release was on average 6.9 µg. Based on the total amount of the embedded FDAc this corresponds to a percentage of almost 8% and clarifies the slow FDAc release (Fig. 3) . For comparison, PLLA/FDAc coated stents with the same coating design were also investigated regarding their FDAc release behaviour by a conventional, wellestablished in vitro method. After a period of 24 h on average 3 µg of FDAc were eluted. This cumulative release corresponds to 3.5% of the embedded FDAc (Fig. 3) .
Discussion
It can be stated that the used perfusion culture system is suitable for the investigation of DES. It allows the balancing of the released drug in the artery segment and the perfusion medium in comparison to the residual drug content in the stent coating. Furthermore, the drug distribution in the artery segment can be demonstrated. However, further studies are required where the artificial, tenside-containing medium has to be replaced by a tissue culture medium and PTX-containing coatings have to be used. Hence, it will be possible to draw conclusions about the distribution behaviour of PTX-containing local drug delivery systems, such as DES and drug-coated balloons (DCB). In summary, it can be concluded that the in vitro model offers valuable approaches for future studies regarding the development of optimized DES or DCB coatings.
